Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy

PLoS Computational Biology

Volumn 11, Issue 3, 2015, Pages

  Fu, Feng ^a   Nowak, Martin A ^b   Bonhoeffer, Sebastian ^a  

^a ETH ZURICH   (Switzerland)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DRUG THERAPY; STOCHASTIC SYSTEMS; TUMORS;

ACQUIRED RESISTANCE; CANCER THERAPY; CELL MIGRATION; DRUG CONCENTRATION; DRUG PENETRATION; DRUG-RESISTANCE; GENETIC HETEROGENEITIES; MICROSCOPIC LEVELS; SPATIAL HETEROGENEITY; TUMOR MICROENVIRONMENTS;

CANCER CELLS;

ARTICLE; CALCULATION; CANCER RESISTANCE; CANCER THERAPY; COMPUTER SIMULATION; CONCEPTUAL FRAMEWORK; DRUG CONCENTRATION; HYPOTHESIS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; PROBABILITY; SYSTEM ANALYSIS; THEORETICAL STUDY; TUMOR MICROENVIRONMENT; BIOLOGY; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; NEOPLASMS; PATHOPHYSIOLOGY; PHYSIOLOGY; SPATIOTEMPORAL ANALYSIS;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; SPATIO-TEMPORAL ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84926308904     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004142     Document Type: Article

References (105)

1. Vogelstein B, et al. Cancer genome landscapes. Science 2013; 339: 1546–1558 doi: 10.1126/science.1235122 23539594
2. Vogelstein B, Kinzler KW, The genetic basis of human cancer. Vol. 821. New York: McGraw-Hill; 2002.
3. Michor F, Iwasa Y, Nowak MA, Dynamics of cancer progression. Nat Rev Cancer 2004; 4: 197–206. doi: 10.1038/nrc1295 14993901
4. Nowak MA, Michor F, Komarova NL, Iwasa Y, Dynamics of tumor suppressor gene inactivation. Proc Natl Acad Sci USA 2004; 101: 10635–10638. doi: 10.1073/pnas.0400747101 15252197
5. Bozic I, et al. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 2010; 107: 18545–18550 doi: 10.1073/pnas.1010978107 20876136
6. Sawyers C, Targeted cancer therapy. Nature 2004; 432(7015): 294–297. doi: 10.1038/nature03095 15549090
7. Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417 doi: 10.1056/NEJMoa062867 17151364
8. Sequist LV, et al. First-line gefitinib in patients with advanced nonsmall-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442–2449 doi: 10.1200/JCO.2007.14.8494 18458038
9. Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626–1634 doi: 10.1200/JCO.2007.14.7116 18316791
10. Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507–2516 doi: 10.1056/NEJMoa1103782 21639808
11. Bozic I, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2013; 2: e00747. doi: 10.7554/eLife.00747 23805382
12. Gottesman MM, Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615–627. doi: 10.1146/annurev.med.53.082901.103929 11818492
13. Holohan C, et al. Cancer drug resistance: an evolving paradigm. Nature Rev Cancer 2013; 13: 714–726 doi: 10.1038/nrc3599
14. Komarova NL, Wodarz D, Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci USA 2005; 102: 9714–9719. doi: 10.1073/pnas.0501870102 15980154
15. Iwasa Y, Nowak MA, Michor F, Evolution of resistance during clonal expansion. Genetics 2006; 172: 2557–2566. doi: 10.1534/genetics.105.049791 16636113
16. Michor F, Nowak MA, Iwasa Y, Evolution of resistance to cancer therapy. Curr Pharm Design 2006; 12: 261–271.
17. Durrett R, Moseley S, Evolution of resistance and progression to disease during clonal expansion of cancer. Theor Popul Biol 2010; 77: 42–48. doi: 10.1016/j.tpb.2009.10.008 19896491
18. Joyce JA, Pollard JW, Microenvironmental regulation of metastasis. Nature Rev Cancer 2009; 9: 239–252. doi: 10.1038/nrc2618
19. Sierra A, Metastases and their microenvironments: linking pathogenesis and therapy. Drug Resist Update 2005; 8: 247–257. doi: 10.1016/j.drup.2005.07.001
20. Quail DF, Joyce JA, Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423–1437. doi: 10.1038/nm.3394 24202395
21. Meads MB, Hazlehurst LA, Dalton WS, The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008; 14: 2519–2526. doi: 10.1158/1078-0432.CCR-07-2223 18451212
22. Trédan O, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441–1454 doi: 10.1093/jnci/djm135 17895480
23. Meads MB, Gatenby RA, Dalton WS, Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009; 9: 665–674 doi: 10.1038/nrc2714 19693095
24. Minchinton AI, Tannock IF, Drug penetration in solid tumours. Nat Rev Cancer 2006; 6(8): 583–92 doi: 10.1038/nrc1893 16862189
25. Zhang Q, et al. Acceleration of emergence of bacterial antibiotic resistance in connected microenvi-ronments. Science 2011; 333: 1764–1767 doi: 10.1126/science.1208747 21940899
26. Greulich P, Waclaw B, Allen RJ, Mutational pathway determines whether drug gradients accelerate evolution of drug-resistant cells. Phys Rev Lett 2012; 109: 088101. doi: 10.1103/PhysRevLett.109.088101 23002776
27. Hermsen R, Deris JB, Hwa T, On the rapidity of antibiotic resistance evolution facilitated by a concentration gradient. Proc Natl Acad Sci USA 2012; 109: 10775–10780. doi: 10.1073/pnas.1117716109 22711808
28. Hallatschek O, Bacteria evolve to go against the grain. Physics 2012; 5: 93. doi: 10.1103/Physics.5.93
29. Nerini, IF, et al. Intratumor Heterogeneity and its Impact on Drug Distribution and Sensitivity. Clinical Pharmacology and Therapeutics, 2014.
30. Pantel K, Alix-Panabiéres C, Riethdorf S, Cancer micrometastases. Nat Rev Clin Oncol 2009; 6: 339–351. doi: 10.1038/nrclinonc.2009.44 19399023
31. Chambers AF, Groom AC, MacDonald IC, Metastasis: dissemination and growth of cancer cells in metastatic sites. Nature Rev Cancer 2002; 2: 563–572. doi: 10.1038/nrc865
32. Landen CN, Birrer MJ, Sood AK, Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26: 995–1005. doi: 10.1200/JCO.2006.07.9970 18195328
33. Klein CA, Parallel progression of primary tumours and metastases. Nature Rev Cancer 2009; 9: 302–312. doi: 10.1038/nrc2627
34. Nguyen DX, Bos PD, Massagué J, Metastasis: from dissemination to organ-specific colonization. Nature Rev Cancer 2009; 9: 274–284. doi: 10.1038/nrc2622
35. Kang YB, Pantel K, Tumor Cell Dissemination: Emerging Biological Insights from Animal Models and Cancer Patients. Cancer Cell 2013; 23: 573–581. doi: 10.1016/j.ccr.2013.04.017 23680145
36. Hanahan D, Weinberg RA, Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674. 21376230
37. Poste G, Fidler IJ, The pathogenesis of cancer metastasis. Nature 1980; 283: 139–146. doi: 10.1038/283139a0 6985715
38. Fidler IJ, The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature Rev Cancer 2003; 3: 453–458.
39. Steeg PS, Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12: 895–904. doi: 10.1038/nm1469 16892035
40. Pantel K, Cote RJ, Fodstad Ø, Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999; 91: 1113–1124. doi: 10.1093/jnci/91.13.1113 10393719
41. Pantel K, Brakenhoff RH, Dissecting the metastatic cascade. Nature Rev Cancer 2004; 4: 448–456. doi: 10.1038/nrc1370
42. Braun S, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793–802 doi: 10.1056/NEJMoa050434 16120859
43. Meng SD, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004; 10: 8152–8162 doi: 10.1158/1078-0432.CCR-04-1110 15623589
44. Kerbel RS, Kobayashi H, Graham CH, Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J Cell Biochem 1994; 56: 37–47. doi: 10.1002/jcb.240560108 7806590
45. Shtivelman E, A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Oncogene 1997; 14: 2167–2173. doi: 10.1038/sj.onc.1201059 9174052
46. Glinsky GV, et al. Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett 1997; 115: 185–193 doi: 10.1016/S0304-3835(97)04738-1 9149123
47. Liang Y, McDonnell S, Clynes M, Examining the relationship between cancer invasion/metastasis and drug resistance. Curr Cancer Drug Targets 2002; 2: 257–277. doi: 10.2174/1568009023333872 12188911
48. Smalley KSM, et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006; 5: 1136–1144 doi: 10.1158/1535-7163.MCT-06-0084 16731745
49. Geyer CE, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–2743 doi: 10.1056/NEJMoa064320 17192538
50. Sahai E, Illuminating the metastatic process. Nature Rev Cancer 2007; 7: 737–749. doi: 10.1038/nrc2229
51. Chaffer CL, Weinberg RA, A perspective on cancer cell metastasis. Science 2011; 331: 1559–1564. doi: 10.1126/science.1203543 21436443
52. Scott JG, et al. A mathematical model of tumour self-seeding reveals secondary metastatic deposits as drivers of primary tumour growth. J R Soc Interface 2013; 10: 20130011 doi: 10.1098/rsif.2013.0011 23427099
53. Scott JG, Kuhn P, Anderson ARA, Unifying metastasisintegrating intravasation, circulation and end-organ colonization. Nature Rev Cancer 2012; 12: 445–446. doi: 10.1038/nrc3287
54. Wu A, et al. Cell motility and drug gradients in the emergence of resistance to chemotherapy. Proc Natl Acad Sci USA 2013; 110: 16103–16108 doi: 10.1073/pnas.1314385110 24046372
55. Laird AK, Dynamics of tumour growth: Comparison of growth rates and extrapolation of growth curve to one cell. Br J Cancer 1965; 19(2): 278. doi: 10.1038/bjc.1965.32 14316202
56. Fournier DV, et al. Growth rate of 147 mammary carcinomas. Cancer 1980; 45(8): 2198–2207. doi: 10.1002/1097-0142(19800415)45:8%3C2198::AID-CNCR2820450832%3E3.0.CO;2-7
57. Friberg S, Mattson S, On the growth rates of human malignant tumors: Implications for medical decision-making. J Surg Oncol 1997; 65(4): 284–97. doi: 10.1002/(SICI)1096-9098(199708)65:4%3C284::AID-JSO11%3E3.0.CO;2-2 9274795
58. Collins VP, Loeffler RK, Tivey H, Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 1956; 76(5): 988–1000. 13362715
59. Schwartz M, A biomathematical approach to clinical tumor growth. Cancer 1961; 14:1272–94. doi: 10.1002/1097-0142(196111/12)14:6%3C1272::AID-CNCR2820140618%3E3.0.CO;2-H 13909709
60. Spratt JS, Spjut HJ, Roper CL, The frequency distribution of the rates of growth and the estimated duration of primary pulmonary carcinomas. Cancer 1963; 16: 687–693. doi: 10.1002/1097-0142(196306)16:6%3C687::AID-CNCR2820160602%3E3.0.CO;2-E 13978529
61. Spratt JS, JrSpratt TL, Rates of growth of pulmonary metastases and host survival. Ann Surg 1964; 159(2): 161. doi: 10.1097/00000658-196402000-00001 14119181
62. Steel GG, Lamerton LF, The growth rate of human tumours. Br J Cancer 1966; 20(1): 74–86. doi: 10.1038/bjc.1966.9 5327764
63. Komarova NL, Katouli AA, Wodarz D, Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia. PLoS ONE 2009; 4(2): e4423. doi: 10.1371/journal.pone.0004423 19204794
64. Iwasa Y, Michor F, Nowak MA, Evolutionary dynamics of escape from biomedical intervention. Proc R Soc Lond Ser B Biol Sci 2003; 270: 2573–2578. doi: 10.1098/rspb.2003.2539
65. Danesh K, Durrett R, Havrilesky LJ, Myers E, A branching process model of ovarian cancer. J Theor Biol 2012; 314: 10–15. doi: 10.1016/j.jtbi.2012.08.025 22959913
66. Foo J, Chmielecki J, Pao W, Michor F, Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J Thorac Oncol 2012; 7: 1583–1593. doi: 10.1097/JTO.0b013e31826146ee 22982659
67. Foo J, Michor F, Evolution of acquired resistance to anti-cancer therapy. J Theor Biol 2014; 355: 10–20. doi: 10.1016/j.jtbi.2014.02.025 24681298
68. Gatenby RA, Silva AS, Gillies RJ, Frieden BR, Adaptive therapy. Cancer Res 2009; 69: 4894–903. doi: 10.1158/0008-5472.CAN-08-3658 19487300
69. Foo J, Leder K, Dynamics of cancer recurrence. Ann Appl Probab 2013; 23: 1437–1468. doi: 10.1214/12-AAP876
70. Foo J, Leder K, Mummenthaler S, Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors. Evolutionary Applications 2013; 6: 54–69. doi: 10.1111/eva.12019 23396647
71. Athreya KB, Ney PE, Branching Processes. Berlin: Springer-Verlag; 1972.
72. Goldie JH, Coldman AJ, Drug resistance in cancer: mechanisms and models. New York: Cambridge University Press; 1998.
73. Iwasa Y, Michor F, Nowak MA, Evolutionary dynamics of invasion and escape. J Theor Biol 2004; 226(2): 205–214. doi: 10.1016/j.jtbi.2003.08.014 14643190
74. Haeno H, et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012; 148(1): 362–375. doi: 10.1016/j.cell.2011.11.060 22265421
75. Hoppe R, Phillips TL, Roach M, III3rd ed. Textbook of Radiation Oncology. United States: Saunders Elsevier; 2010.
76. Hermsen R, Hwa T, Sources and sinks: a stochastic model of evolution in heterogeneous environments. Phys Rev Lett 2010; 105(24): 248104. doi: 10.1103/PhysRevLett.105.248104 21231560
77. Roose T, Chapman SJ, Maini PK, Mathematical models of avascular tumor growth. SIAM Review 2007; 49(2): 179–208. doi: 10.1137/S0036144504446291
78. Anderson AR, A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion. Math Med Biol 2005; 22(2): 163–186. doi: 10.1093/imammb/dqi005 15781426
79. Anderson AR, Weaver AM, Cummings PT, Quaranta V, Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006; 127(5): 905–915. doi: 10.1016/j.cell.2006.09.042 17129778
80. Delitala M, Lorenzi T, A mathematical model for the dynamics of cancer hepatocytes under therapeutic actions. J Theor Biol 2012; 297: 88–102. doi: 10.1016/j.jtbi.2011.11.022 22138092
81. Lorz A, Lorenzi T, Hochberg ME, Clairambault J, Perthame B, Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies. Math Model Numer Anal 2013; 47: 377–399. doi: 10.1051/m2an/2012031
82. Thalhauser CJ, Lowengrub JS, Stupack D, Komarova NL, Selection in spatial stochastic models of cancer: Migration as a key modulator of fitness. Biology Direct 2010; 5: 21. doi: 10.1186/1745-6150-5-21 20406439
83. Baum M, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131–2139 doi: 10.1016/S0140-6736(02)09088-8 12090977
84. Feldmann G, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007; 67: 2187–2196 doi: 10.1158/0008-5472.CAN-06-3281 17332349
85. Moreno-Gamez, S, et al. Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multi-drug resistance. Preprint at BioRxiv; 2014.
86. Bonhoeffer S, et al. Evidence for positive epistasis in HIV-1. Science 2004; 306: 1547–1550 doi: 10.1126/science.1101786 15567861
87. Woodhouse EC, Chuaqui RF, Liotta LA, General mechanisms of metastasis. Cancer 1997; 80: 1529–1537. doi: 10.1002/(SICI)1097-0142(19971015)80:8+%3C1529::AID-CNCR2%3E3.0.CO;2-F 9362419
88. Chambers AF, et al. Clinical targets for anti-metastasis therapy. Adv Cancer Res 2000; 79: 91–121 doi: 10.1016/S0065-230X(00)79003-8 10818678
89. Wells A, et al. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci 2013; 34: 283289 doi: 10.1016/j.tips.2013.03.001
90. Michor F, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267–1270 doi: 10.1038/nature03669 15988530
91. Jordan CF, Guzman ML, Noble M, Cancer stem cells. N Engl J Med 2006; 355: 1253–1261. doi: 10.1056/NEJMra061808 16990388
92. Visvader JE, Lindeman GJ, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Rev Cancer 2008; 8: 755–768. doi: 10.1038/nrc2499
93. Zhou D, Wang Y, Wu B, A multi-phenotypic cancer model with cell plasticity. J Theor Biol 2014; 357: 35–45. doi: 10.1016/j.jtbi.2014.04.039 24819463
94. Komarova NL, Wodarz D, Effect of cellular quiescence on the success of targeted CML therapy. PLoS ONE 2007; 2: e990. doi: 10.1371/journal.pone.0000990 17912367
95. Aguirre-Ghiso JA, Models, mechanisms and clinical evidence for cancer dormancy. Nature Rev Cancer 2007; 7: 834–846. doi: 10.1038/nrc2256
96. Al-Hajj M, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983–3988 doi: 10.1073/pnas.0530291100 12629218
97. Wong CW, et al. Apoptosis: an early event in metastatic inefficiency. Cancer Res 2001; 61: 333–338 11196183
98. Luzzi KJ, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998; 153: 865–873 doi: 10.1016/S0002-9440(10)65628-3 9736035
99. Regoes RR, et al. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 2004; 48(10): 3670–3676. doi: 10.1128/AAC.48.10.3670-3676.2004 15388418
100. Hill BT, Whelan RD, Shellard SA, McClean S, Hosking LK, Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 1994; 12(3): 169–182. doi: 10.1007/BF00873957 7896535
101. Goutelle S, et al. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol 2008; 22(6): 633–648. doi: 10.1111/j.1472-8206.2008.00633.x 19049668
102. Hill BT, et al. Establishment and characterisation of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies. Int J Cancer 1987; 39(2): 219–225. doi: 10.1002/ijc.2910390216 3804493
103. Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA, Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med 2012; 18: 1378–1385. doi: 10.1038/nm.2892 22941277
104. Antal T, Krapivsky PL, Exact solution of a two-type branching process: Clone size distribution in cell division kinetics. J Stat Mech 2010: P07028.
105. Conway JM, Coombs D, A Stochastic model of latently infected cell reactivation and viral blip generation in treated HIV patients. PLoS Comput Biol 2011; 7: e1002033. doi: 10.1371/journal.pcbi.1002033 21552334